Merck KGaA appoints Maya Martinez-Davis as global head of oncology

14 April 2016
maya-martinez-davis-large

Maya Martinez-Davis has been appointed as global head of oncology of the biopharma business of Germany's life science company Merck KGaA (MRK: DE), it was announced on Thursday.

Taking over from Andrew Schiermeier, her responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches.

This will start with avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck KGaA, and currently managed under a strategic alliance with Pfizer (NYSE: PFE).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical